Skip to main content

Table 6 Association between different CYP2C9, CYP1A2, CYP3A4 and CYP2C19 SNP genotypes and the clinico-pathological features of breast cancer (BC)

From: Association of CYP gene polymorphisms with breast cancer risk and prognostic factors in the Jordanian population

Clinical features

CYP2C9

CYP1A2

CYP1B1

CYP3A4

CYP2C19

rs1799853

rs762551

rs10175368

rs35599367

rs4244285

Body mass index b

n = 221

0.078

0.178

0.552

0.286

0.834

Age at first pregnancy b

n = 195

0.144

0.292

0.179

0.032

0.785

Age at BC diagnosis b

n = 221

0.511

0.675

0.295

0.391

0.132

Allergy a

n = 221

0.721

0.927

0.859

0.146

0.920

Age at menarche b

n = 221

0.834

0.738

0.905

0.869

0.931

Breastfeeding status a

n = 221

0.250

0.450

0.196

0.009

0.161

Age at menopause b

n = 108

0 .356

0 .034

0 .554

0 .161

0 .266

Family history a

n = 221

0.562

0.167

0.521

0.494

0.294

Co-morbidity a

n = 221

0.659

0.456

0.774

0.822

0.349

Smoking a

n = 216

0.305

0.705

0.899

0.341

0.528

Pathological features

Progesterone receptor status a

n = 198

0.213

0.118

0.378

0.554

0.213

Estrogen receptor status a

n = 191

0.409

0.208

0.286

0.511

0.409

Human epidermal growth factor receptor 2 marker (HER2) a

n = 139

0.495

0.028

0.109

0.566

0.495

Heteromolecular BC markersa

n = 138

0.691

0.043

0.024

0.914

0.081

Tumor differentiation a

n = 197

0.285

0.577

0.498

0.734

0.285

Axillary lymph nodes a

n = 221

0.956

0.587

0.179

0.346

0.956

Tumor stage a

n = 208

0.743

0.153

0.469

0.048

0.743

Histology classification a

n = 209

0.708

0.011

0.238

0.118

0.708

Tumor size b

n = 208

0.407

0.433

0.991

0.318

0.407

Lymph node involvement a

n = 221

0.194

0.001

0.406

0.516

0.194

  1. a Pearson’s chi-squared test was used to determine genotype-phenotype association
  2. b Analysis of variance (ANOVA) test was used to determine genotype-phenotype association
  3. P-Value < 0.0045 considered as significant